Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise

Zenas BioPharma (ZBIO) is positioned as more than a rare-disease play, leveraging obexelimab’s B-cell inhibition platform for multiple autoimmune indications. ZBIO’s Phase 3 INDIGO trial validates obexelimab in IgG4-RD, showing 56% flare reduction and improved safety versus placebo, supporting a differentiated mechanism. With $718.5M cash and milestone access, ZBIO expects runway through Q2 2029, enabling launch prep and expansion into SLE and MS indications. Valuation is premium, but justified by late-stage assets, BLA submission, and platform potential; key catalysts include FDA review and pivotal SLE data in late 2026. My optimistic outlook for Zenas BioPharma ( ZBIO ) stems from a very basic yet frequently overlooked concept: Zenas is doing much more than simply developing an individual rare-disease drug. Zenas is utilizing IgG4-related disease (IgG4-RD) as a first commercially viable proof